Reductionofphosphate intake:
Many cats in Stage 2 will have normal plasma phosphate concentrations but will have
increased plasma PTH concentration. Evidence suggests that chronic reduction of
phosphate intake to maintain a plasma phosphate concentration below 1.5 mmol/l
(but not less than 0.9 mmol/l; <4.6 mg/dl but >2.7 mg/dl) is beneficial to patients with
CKD.
The following measures can be introduced sequentially in an attempt to achieve this:
1. Dietary phosphate restriction (i.e., clinical renal diet therapy).
2.
If plasma phosphate concentration remains above 1.5 mmol/l (4.6 mg/dl) after
dietary restriction, give enteric phosphate binders (such as aluminum hydroxide,
aluminum carbonate, calcium carbonate, calcium acetate, lanthanum carbonate)
to effect, starting at 30-60 mg/kg/day in divided doses to be mixed with each
meal (mixed with the food). The dose required will vary according to the amount
of phosphate being fed and the stage of kidney disease. Treatment with
phosphate binders should be to effect (as outlined above), with signs of toxicity
limiting the upper dose rate possible in a given patient. Monitor serum calcium
and phosphate concentrations every 4-6 weeks until stable and then every 12
weeks. Microcytosis and/or generalized muscle weakness and neurological
signs suggest aluminum toxicity if using an aluminum containing binder – switch
to another form of phosphate binder should this occur. It should be noted,
however, unlike the dog, aluminum toxicity has not been reported in the cat and it
is possible to measure blood aluminum levels to confirm suspected cases.
Hypercalcemia should be avoided – combinations of aluminum and calcium
containing phosphate binders may
be necessary in some cases.
я не вижу ни одно упоминание о ФОСФАТЕ алюминия
http://www.iris-kidney.com/pdf/IRIS_CAT ... s_2019.pdf